Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Amortizatization of Intangibles (2021 - 2025)

Amylyx Pharmaceuticals has reported Amortizatization of Intangibles over the past 5 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Amortizatization of Intangibles at $1.1 million for Q4 2025, down 40.98% from a year ago — trailing twelve months through Dec 2025 was $5.5 million (down 43.93% YoY), and the annual figure for FY2025 was $5.5 million, down 43.93%.
  • Amortizatization of Intangibles for Q4 2025 was $1.1 million at Amylyx Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Over the last five years, Amortizatization of Intangibles for AMLX hit a ceiling of $3.2 million in Q2 2024 and a floor of -$98000.0 in Q4 2021.
  • Median Amortizatization of Intangibles over the past 5 years was $1.8 million (2024), compared with a mean of $1.6 million.
  • Biggest five-year swings in Amortizatization of Intangibles: skyrocketed 145250.0% in 2023 and later crashed 52.08% in 2025.
  • Amylyx Pharmaceuticals' Amortizatization of Intangibles stood at -$98000.0 in 2021, then soared by 1997.96% to $1.9 million in 2022, then skyrocketed by 38.28% to $2.6 million in 2023, then crashed by 30.37% to $1.8 million in 2024, then crashed by 40.98% to $1.1 million in 2025.
  • The last three reported values for Amortizatization of Intangibles were $1.1 million (Q4 2025), $1.2 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.